D Birnbaum

Summary

Country: France

Publications

  1. pmc Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cgamma at the centrosome
    Hélène Lelièvre
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Mol Cancer 7:30. 2008
  2. pmc Reasons for breast cancer heterogeneity
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Universite de la Mediterranee, 13009 Marseille, France
    J Biol 7:6. 2008
  3. pmc Direct and heterologous approaches to identify the LET-756/FGF interactome
    Cornel Popovici
    Institut de Cancérologie de Marseille, Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes et UMR599 Inserm, 27 Bd Lei Roure, 13009 Marseille, France
    BMC Genomics 7:105. 2006
  4. pmc FGFR1 and WT1 are markers of human prostate cancer progression
    Elizabeth Devilard
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm et Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:272. 2006
  5. pmc Nectin-4 is a new histological and serological tumor associated marker for breast cancer
    Stéphanie Fabre-Lafay
    INSERM, UMR599, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 7:73. 2007
  6. pmc Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin
    Azza Ben Hamida
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm, Marseille, France
    BMC Cancer 8:28. 2008
  7. pmc Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
    Anne Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:245. 2006
  8. pmc A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
    Anthony Goncalves
    Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France
    BMC Cancer 8:169. 2008
  9. pmc Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications
    Mélanie Nugoli
    Equipe Genome et Cancer, UMR 5535, CNRS and EMI 0229, INSERM, Centre de Recherche CRLC Val d Aurelle, Montpellier, France
    BMC Cancer 3:13. 2003
  10. ncbi "Paleogenomics": looking in the past to the future
    D Birnbaum
    U 119 INSERM, 13009 Marseille, France
    J Exp Zool 288:21-2. 2000

Detail Information

Publications154 found, 100 shown here

  1. pmc Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cgamma at the centrosome
    Hélène Lelièvre
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Mol Cancer 7:30. 2008
    ..This protein comprises the N-terminal region of the centrosomal protein FOP and the tyrosine kinase of the FGFR1 receptor. FOP-FGFR1 is localized at the centrosome where it exerts a constitutive kinase activity...
  2. pmc Reasons for breast cancer heterogeneity
    Francois Bertucci
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Universite de la Mediterranee, 13009 Marseille, France
    J Biol 7:6. 2008
    ..Two recent papers have contributed to the establishment of a more precise molecular classification of breast tumors...
  3. pmc Direct and heterologous approaches to identify the LET-756/FGF interactome
    Cornel Popovici
    Institut de Cancérologie de Marseille, Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes et UMR599 Inserm, 27 Bd Lei Roure, 13009 Marseille, France
    BMC Genomics 7:105. 2006
    ..However, many aspects of their activities are not well defined. LET-756, one of the two C. elegans FGFs, is expressed throughout development and is essential for worm development. It is both expressed in the nucleus and secreted...
  4. pmc FGFR1 and WT1 are markers of human prostate cancer progression
    Elizabeth Devilard
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm et Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:272. 2006
    ..Androgen-independent prostate adenocarcinomas are responsible for about 6% of overall cancer deaths in men...
  5. pmc Nectin-4 is a new histological and serological tumor associated marker for breast cancer
    Stéphanie Fabre-Lafay
    INSERM, UMR599, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 7:73. 2007
    ..Nectins are cell adhesion molecules involved in the regulation of epithelial physiology. We present here Nectin-4/PVRL4 as a new histological and serological tumor associated marker for breast carcinoma...
  6. pmc Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin
    Azza Ben Hamida
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm, Marseille, France
    BMC Cancer 8:28. 2008
    ..The aim of this study was to determine the distribution of molecular subtypes in IBC and identify factors that may explain the poor prognosis of IBC...
  7. pmc Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
    Anne Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:245. 2006
    ..Amplification status may provide diagnostic and prognostic information and may lead to new treatment strategies. Chromosomal regions 8p12, 8q24, 11q13, 17q12 and 20q13 are recurrently amplified in breast cancers...
  8. pmc A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment
    Anthony Goncalves
    Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France
    BMC Cancer 8:169. 2008
    ..Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants of cetuximab activity...
  9. pmc Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications
    Mélanie Nugoli
    Equipe Genome et Cancer, UMR 5535, CNRS and EMI 0229, INSERM, Centre de Recherche CRLC Val d Aurelle, Montpellier, France
    BMC Cancer 3:13. 2003
    ..Both phenotypic and cytogenetic variability have been reported for clones of breast carcinoma cell lines but have not been comprehensively studied. Despite this, cell lines such as MCF-7 cells are extensively used as model systems...
  10. ncbi "Paleogenomics": looking in the past to the future
    D Birnbaum
    U 119 INSERM, 13009 Marseille, France
    J Exp Zool 288:21-2. 2000
    ..And yet, will not the power of deduction and reconstitution of information gained through man's sophisticated technologies one day recreate a "virtual" metazoan ancestor?..
  11. ncbi Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis
    J D Jacquemier
    Departement de Pathologie, Institut Paoli Calmettes, Marseille, France
    J Pathol 184:130-5. 1998
    ..This suggests that the MVC may predict the degree of resistance to chemotherapy. Patients with high levels of angiogenesis, particularly node-negative patients, might therefore be able to benefit from adjuvant therapy of another kind...
  12. ncbi A pair as a minimum: the two fibroblast growth factors of the nematode Caenorhabditis elegans
    Daniel Birnbaum
    Molecular Oncology Laboratory, UMR599 Inserm, 27 Bd Lei Roure, 13009 Marseille, France
    Dev Dyn 232:247-55. 2005
    ..Phylogenetic and functional studies suggest that LET-756, like vertebrate FGF9, -16, and -20, belongs to the FGF9 family, whereas EGL-17, like vertebrate FGF8, -17, and -18, could be included in the FGF8 family...
  13. ncbi Basal and luminal breast cancers: basic or luminous? (review)
    Daniel Birnbaum
    Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and UMR599 INSERM, 13009 Marseille, France
    Int J Oncol 25:249-58. 2004
    ..The combined effects of these progresses on our understanding of breast cancer biology should have major consequences on the way this disease is managed...
  14. ncbi Chromosome arm 8p and cancer: a fragile hypothesis
    Daniel Birnbaum
    Department of Molecular Oncology, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Lancet Oncol 4:639-42. 2003
    ..We have found that chromosome breaks disrupt the NRG1 gene at 8p12 in breast and pancreatic cancers. We hypothesise that alteration of the NRG1 gene could occur through breakage at a non-common fragile site...
  15. ncbi Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase
    E Fournier
    Laboratoire d Oncologie Moleculaire, U119 INSERM, 27 Bd Lei Roure, 13009 Marseille, France
    J Biol Chem 271:12956-63. 1996
    ....
  16. pmc 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways
    G Guasch
    Laboratoire d Oncologie Moleculaire, INSERM U 119, IFR 57, Marseille, France
    Mol Cell Biol 21:8129-42. 2001
    ..Elucidation of signaling events downstream of FOP-FGFR1 constitutive activation provides insight into the mechanism of leukemogenesis mediated by this oncogenic fusion protein...
  17. ncbi The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins
    F Jaulin-Bastard
    U119 INSERM, Molecular Oncology, Institut Paoli Calmettes, 27 Boulevard Lei Roure, 13009 Marseille, France
    J Biol Chem 276:15256-63. 2001
    ..Since ERBIN and PICK1 tend to oligomerize, further complexity of protein networks may participate in ERBB2/HER2 functions and specificity...
  18. ncbi The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells
    C Lavagna-Sévenier
    Laboratory of Molecular Oncology, INSERM U119, 13009 Marseille, France
    J Biol Chem 273:14962-7. 1998
    ....
  19. ncbi Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer
    A Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm et Institut Paoli Calmettes, Marseille, France
    Oncogene 26:298-307. 2007
    ..Loss of Afadin had prognostic impact, suggesting that AF-6 may be a TSG. Loss of Afadin was correlated with loss of FHIT expression, suggesting fragility of FRA6E and FRA3B in a certain proportion of breast tumors...
  20. ncbi Structure and developmental expression of mouse Garp, a gene encoding a new leucine-rich repeat-containing protein
    R Roubin
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Int J Dev Biol 40:545-55. 1996
    ..In the adult it is expressed in the megakaryocytes of the spleen and in endothelial cells of the placenta. The data suggests that GARP might be involved in platelet-endothelium interactions...
  21. ncbi Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase
    N Maroc
    Molecular Hematology Laboratory, Unite 119 INSERM, Marseille, France
    Oncogene 8:909-18. 1993
    ..Finally, expression analysis of the FLT3 protein shows that, in addition to the hematopoietic system, FLT3 is strongly expressed in neural, gonadal, hepatic and placental tissues in the mouse...
  22. ncbi SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor
    S Marchetto
    Laboratoire d Oncologie Moleculaire, INSERM U119, Marseille, France
    Leukemia 13:1374-82. 1999
    ..In addition, our study provides the structural bases for SHC phosphorylation and formation of the SHC/SHIP complex...
  23. ncbi Lano, a novel LAP protein directly connected to MAGUK proteins in epithelial cells
    H Saito
    U119 INSERM, Molecular Oncology, 27 Boulevard Lei Roure, 13009 Marseille, France
    J Biol Chem 276:32051-5. 2001
    ....
  24. ncbi FGF6 modulates the expression of fibroblast growth factor receptors and myogenic genes in muscle cells
    S Pizette
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Exp Cell Res 224:143-51. 1996
    ..These results suggest that intramuscular FGF6 concentrations could influence the proliferation and differentiation processes taking place during development...
  25. ncbi ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor
    J P Borg
    U119 INSERM, Molecular Oncology, Marseille, France
    Nat Cell Biol 2:407-14. 2000
    ..We suggest that ERBIN acts in the localization and signalling of ERBB2/HER2 in epithelia...
  26. ncbi The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor
    F Galland
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Oncogene 8:1233-40. 1993
    ..The FLT4 protein, when transiently expressed in Cos-7 cells and immunoprecipitated with a FLT4-specific rabbit immune serum, has an apparent molecular weight of 170 kDa...
  27. ncbi Characterization of the HST-related FGF.6 gene, a new member of the fibroblast growth factor gene family
    I Marics
    U 119 INSERM, Marseille, France
    Oncogene 4:335-40. 1989
    ..FGF.6 was mapped to chromosome 12 at band p13 by in situ hybridization. The cloned normal human gene was able to transform mouse NIH3T3 fibroblasts using both focus- and tumorigenicity-assays...
  28. ncbi The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins
    V Ollendorff
    Laboratoire d Oncologie Moleculaire, Institut National de la Sante et de la Recherche Medicale, Marseille, France
    Cell Growth Differ 5:213-9. 1994
    ..The GARP protein has structural similarities with the human GP Ib alpha and GP V platelet proteins, and with the Chaoptin, Toll, and Connectin adhesion molecules of Drosophila...
  29. ncbi Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling
    E Fournier
    Molecular Oncology Laboratory, INSERM U 119, Marseille, France
    Oncogene 18:507-14. 1999
    ..Mutation of the two phosphorylation sites increases this effect, suggesting that they have a synergistic role...
  30. ncbi Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation
    V Ollendorff
    Laboratoire d Oncologie Moleculaire, U119 INSERM, Institut de Cancérologie et d Immunologie, 27 Boulevard Lei Roure, 13009 Marseille, France
    J Biol Chem 274:26922-30. 1999
    ..Taken together, these results indicate that FIM-FGFR1 is activated by dimerization as a cytoplasmic kinase and suggest that FIM-FGFR1 partially signals through the FGFR1 pathways...
  31. ncbi FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33)
    G Guasch
    Laboratoire d Oncologie Moleculaire, INSERM U119, Institut de Cancérologie et d Immunologie de Marseille, Marseille, France
    Blood 95:1788-96. 2000
    ..Transient expression studies show that the CEP110-FGFR1 protein has a constitutive kinase activity and is located within the cell cytoplasm. (Blood. 2000;95:1788-1796)..
  32. ncbi Chromosomal localization of the hst oncogene and its co-amplification with the int.2 oncogene in a human melanoma
    J Adelaide
    Unité 119 de l INSERM, Marseille, France
    Oncogene 2:413-6. 1988
    ..This is also the location of the int.2 gene. Furthermore, the two genes are co-amplified in a human melanoma, raising the possibility that amplification in human tumors may be a mechanism of activation of genes of the FGF family...
  33. ncbi Characterization of the mouse Cblc/Cbl3 gene
    F Fiore
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, IFR57, 27 Boulevard Lei Roure, 13009 Marseille, France
    Biochem Biophys Res Commun 280:182-7. 2001
    ..Mouse Cblc mRNA is expressed in embryo and adult tissues and has a rather ubiquitous distribution...
  34. ncbi Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively
    M G Mattei
    U 406 Inserm, Hopital d Enfants de la Timone, Marseille, France
    Genomics 32:168-9. 1996
  35. ncbi Expression of the Fgf6 gene is restricted to developing skeletal muscle in the mouse embryo
    O Delapeyriere
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Development 118:601-11. 1993
    ..In addition, recombinant FGF6 protein is able to repress the terminal differentiation of myoblasts in culture, providing additional support to the concept that FGF6 plays an important role in myogenesis...
  36. ncbi ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines
    C Ginestier
    UMR599 Inserm, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, Marseille, France
    Oncogene 26:7163-9. 2007
    ..We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein...
  37. ncbi Histological type and syncytial growth pattern affect E-cadherin expression in a multifactorial analysis of a combined panel of sporadic and BRCA1-associated breast cancers
    J Jacquemier
    Department of Pathology, Paoli Calmettes Institute, Marseille, France
    Int J Cancer 83:45-9. 1999
    ..0001), in agreement with previous results, and syncytial growth pattern (SGP) (p = 0.01). The latter result provides a biological basis for SGP, the cardinal feature of medullary breast carcinoma...
  38. ncbi MSH2 and MLH1 immunodetection and the prognosis of colon cancer
    J Perrin
    Departement d'Oncologie Moleculaire, Institut Paoli-Calmettes (IPC, Universite de la Mediterranee, Marseille Cedex 9, France
    Int J Oncol 19:891-5. 2001
    ..MSH2 and/or MLH1 negative tumors were frequently tumors of the proximal colon; in this subpopulation or proximal tumors, MSH2 and/or MLH1 negativity was associated with a longer disease-free survival...
  39. ncbi Assignment of the centrosomal protein 110 gene (Cep110) to mouse chromosome bands 2B-C1 by in situ hybridization
    C Popovici
    INSERM U119, Marseille, France
    Cytogenet Cell Genet 89:216-7. 2000
  40. doi Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth
    G Fournier
    INSERM, UMR 891, Laboratoire d Oncologie Moleculaire, CRCM, Marseille, France
    Oncogene 30:3862-74. 2011
    ..These results may explain why the loss of afadin expression in tumors correlates with high tumor size and poor metastasis-free survival in patients...
  41. ncbi Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase
    R Rottapel
    Molecular Hematology Laboratory, Unite 119 INSERM, Marseille, France
    Oncogene 9:1755-65. 1994
    ..FF3 associates with PI3K activity and the SH2 domains of p85 and Grb-2. Phosphopeptide competition experiments suggest that the PI3K binding site is located outside of the kinase insert in the carboxy tail of the receptor...
  42. ncbi Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse
    O Rosnet
    Laboratory of Molecular Oncology, U 119 INSERM, Marseille, France
    Oncogene 8:173-9. 1993
    ..The physical linkage is also evidenced in mouse, where the two genes appear to lie within a 350 kb Mlu I fragment, on mouse chromosome 5...
  43. ncbi Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
    F Birg
    Laboratory of Molecular Hematology, , Marseille, France
    Blood 80:2584-93. 1992
    ....
  44. ncbi Integrated map of the chromosome 8p12-p21 region, a region involved in human cancers and Werner syndrome
    A Imbert
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Genomics 32:29-38. 1996
    ..The reported map and contigs of YACs should facilitate the search for putative genes involved in sporadic and familial breast cancer as well as in the Werner syndrome...
  45. ncbi The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1
    C Popovici
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Institut de Cancérologie et d Immunologie de Marseille, France
    Blood 93:1381-9. 1999
    ..It may promote hematopoietic stem cell proliferation and leukemogenesis through a constitutive phosphorylation and activation of the downstream pathway of FGFR1...
  46. pmc Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)
    C Popovici
    Laboratoire d Oncologie Moleculaire, Unite 119, Institut National de la Sante et de la Recherche Medicale, Institut de Cancérologie et Immunologie, 232 Boulevard Sainte Marguerite, 13009 Marseille, France
    Proc Natl Acad Sci U S A 95:5712-7. 1998
    ..The FIM/FGFR1 fusion protein contains the FIM putative zinc finger motifs and the catalytic domain of FGFR1. We show that it has a constitutive tyrosine kinase activity...
  47. ncbi Prognosis of breast-carcinoma lymphagenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3
    J Jacquemier
    Pathology Department, Institut Paoli Calmettes, Marseille, France
    Int J Cancer 89:69-73. 2000
    ..5 and of MLC, 40.5. There was no quantitative correlation between these 2 parameters. The MVC but not the MLC had a prognostic value in overall survival. Neither the MLC nor the MVC had any correlation with axillary-lymph-node invasion...
  48. doi Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases
    A Murati
    Département d Oncologie Moléculaire, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France
    Leukemia 23:85-94. 2009
    ..These features, reminiscent of T-cell acute lymphoid leukemia (ALL), suggest the targeting of a common T-myeloid progenitor...
  49. pmc Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles
    F Bertucci
    INSERM UMR891, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France
    Oncogene 27:5359-72. 2008
    ..Although ILCs and IDCs share common alterations, our data show that ILCs and IDCs could be distinguished on the basis of their genomic and expression profiles suggesting that they evolve along distinct genetic pathways...
  50. ncbi [Molecular typing of breast cancer: transcriptomics and DNA microarrays]
    F Bertucci
    Laboratoire de biologie des tumeurs Institut Paoli-Calmettes, IFR57, 13009 Marseille
    Bull Cancer 88:277-86. 2001
    ..Expression profiles will help classify tumors and provide new prognostic tools and potential therapeutic targets. They will also boost our knowledge of the molecular events responsible for the development and progression of this cancer...
  51. ncbi Apparent normal phenotype of Fgf6-/- mice
    F Fiore
    Laboratoire d Oncologie Moleculaire, U119 INSERM, Marseille, France
    Int J Dev Biol 41:639-42. 1997
    ..The animals are viable, fertile and apparently normal, indicating that FGF6 is not required for vital functions in the laboratory mouse...
  52. ncbi [Impact of recent oncogenetic progress on the management of high risk breast cancer patients: the example of BRCA1 and BRCA2 genes]
    H Sobol
    Département d Oncologie Génétique INSERM CRI 9703, Institut Paoli Calmettes, Marseille, France
    Ann Endocrinol (Paris) 59:459-64. 1998
    ..These elements may be of valuable help in the design of strategies in the medical management of cancer prone individuals...
  53. ncbi Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues
    O Delapeyriere
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Differentiation 58:351-9. 1995
    ..Our observations allow for a comparison with the distribution of the Kit gene and analysis of a possible redundancy between KIT and FLT3 receptors...
  54. ncbi Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase
    J P Borg
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Oncogene 10:973-84. 1995
    ..Flt4 transcripts were found at day 12.5 post-coïtum and thereafter, including the adult mouse, predominantly in the pericardium, pleural membranes and in the lung...
  55. ncbi Detection of a low frequency of activated ras genes in human melanomas using a tumorigenicity assay
    F Raybaud
    Unité 119 de l INSERM, Marseille, France
    Cancer Res 48:950-3. 1988
    ..No N-ras genes mutated at codon 13 were detected. Thus, the tumorigenicity assay detects a low frequency of ras gene activation in melanomas...
  56. ncbi Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene
    O Rosnet
    U 119 INSERM, Marseille, France
    Genomics 9:380-5. 1991
    ..We have localized the human FLT3 gene to chromosome 13, band q12, and its mouse homolog to chromosome 5, region G...
  57. ncbi The human and mouse fibroblast growth factor 6 (FGF6) genes and their products: possible implication in muscle development
    F Coulier
    Laboratoire d Oncologie Moleculaire, Unité 119 de l INSERM, Marseille, France
    Prog Growth Factor Res 5:1-14. 1994
    ..It represses the terminal differentiation of myoblasts. Action of FGF6 could be mediated by the FGFR4 receptor, which binds FGF6 and whose gene is also expressed in developing skeletal muscle...
  58. pmc A seven-gene prognostic model for platinum-treated ovarian carcinomas
    R Sabatier
    Department of Molecular Oncology, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, 13009 Marseille, France
    Br J Cancer 105:304-11. 2011
    ..We analysed gene expression profiles of ovarian carcinomas to identify a multigene expression model associated with survival after platinum-based therapy...
  59. ncbi Activation of a mcf.2 oncogene by deletion of amino-terminal coding sequences
    T Noguchi
    U 119 de l INSERM, Marseille, France
    Oncogene 3:709-15. 1988
    ..G. Vecchio, D. Rao, S. Tronick & S. Aaronson (1988) Proc. Natl. Acad. Sci. USA, 85, 2061-2065) revealed that mcf.2 and dbl represent two different activated versions of the same proto-oncogene...
  60. ncbi WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type
    F Ugolini
    Laboratoire d Oncologie Moleculaire, INSERM U 119, IFR 57, 27 Boulevard Lei Roure, 13009, Marseille, France
    Oncogene 20:5810-7. 2001
    ..Conversely, the maintenance of SFRP1 in carcinomas is correlated with the presence of lymphoplasmocytic stroma. No significant association was observed between SFRP1 status and the level of apoptosis in tumoral cells...
  61. ncbi let-756, a C. elegans fgf essential for worm development
    R Roubin
    Laboratoire d Oncologie Moleculaire, U119 INSERM, Marseille, France
    Oncogene 18:6741-7. 1999
    ..It causes a developmental arrest early in the larval stages. Thus, in contrast to the other nematode fgf gene egl-17, let-756/fgf is essential for worm development...
  62. ncbi Identification and characterization of a functional murine FLT3 isoform produced by exon skipping
    C Lavagna
    Laboratoire d Oncologie Moleculaire, INSERM U 119, Marseille, France
    J Biol Chem 270:3165-71. 1995
    ..Ligand-induced tyrosine phosphorylation of the two isoforms was equivalent in COS-1 transfected cells, indicating that the fifth Ig-like domain is not strictly necessary for either ligand-binding or kinase activation...
  63. ncbi Homeobox gene clusters and the human paralogy map
    C Popovici
    , U119 INSERM, Marseille, France
    FEBS Lett 491:237-42. 2001
    ..We tentatively assembled several paralogons in superparalogons. One of the superparalogons contains the contraHOX genes. These observations were extended to hundreds of genes, and allowed to describe a primary human genome paralogy map...
  64. ncbi The human FGF9 gene maps to chromosomal region 13q11-q12
    M G Mattei
    U 242 INSERM, Hopital d Enfants de la Timone, Marseille, France
    Genomics 29:811-2. 1995
  65. ncbi MOZ is fused to p300 in an acute monocytic leukemia with t(8;22)
    M Chaffanet
    Laboratoire d Oncologie Moleculaire, INSERM U119, Marseille, France
    Genes Chromosomes Cancer 28:138-44. 2000
    ..This result defines a novel reciprocal translocation involving two acetyltransferases, MOZ and p300, resulting in an abnormal transcriptional co-activator that could play a critical role in leukemogenesis...
  66. ncbi Skeletal muscle regeneration is not impaired in Fgf6 -/- mutant mice
    F Fiore
    U 119 INSERM, Universite de la Mediterranee, Marseille, France
    Biochem Biophys Res Commun 272:138-43. 2000
    ..Our study suggests that FGF6 does not play a role in muscle regeneration, i.e., in satellite cell proliferation and fusion, or that this role is strictly compensated by other factors, possibly other FGFs...
  67. ncbi Myeloproliferative disorders: the centrosome connection
    B Delaval
    Laboratory of Molecular Oncology, UMR599 Inserm, Marseille Cancer Institute, Institut Paoli Calmettes, Marseille, France
    Leukemia 19:1739-44. 2005
    ..The same effect might be triggered by other fusion kinases in other MPD and non-MPD malignancies...
  68. doi KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570
    A Chaix
    1 INSERM, U1068, Centre de Recherche en Cancerologie de Marseille, Marseille, France 2 Institut Paoli Calmettes, Marseille, France 3 Aix Marseille University, Marseille, France
    Oncogene 33:872-81. 2014
    ..Our results support the hypothesis that, KIT-D816V mutation is a mild oncogenic event that is sufficient to confer partial transforming properties, but requires additional mutations to acquire its full transforming potential...
  69. ncbi Gene expression profiling of breast cell lines identifies potential new basal markers
    E Charafe-Jauffret
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Inserm Institut Paoli Calmettes, Marseille, France
    Oncogene 25:2273-84. 2006
    ....
  70. ncbi Mouse Fgf7 (fibroblast growth factor 7) and Fgf8 (fibroblast growth factor 8) genes map to chromosomes 2 and 19 respectively
    M G Mattei
    U 242 INSERM, Hopital d Enfants de la Timone, Marseille, France
    Mamm Genome 6:196-7. 1995
  71. doi Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis
    J Gillibert-Duplantier
    INSERM U891, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Oncogene 31:3516-24. 2012
    ..Finally, sST2 was found at high levels in the serum of metastatic breast cancer patients. Our data suggest that sST2 contributes to breast cancer cell motility and that sST2 secretion is associated with metastasis...
  72. ncbi Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family
    O Rosnet
    U 119 INSERM, Marseille, France
    Oncogene 6:1641-50. 1991
    ..7 kb long, except in the testis, where two shorter post-meiotic transcripts are detected. These results suggest a role for this novel receptor and its yet unidentified ligand in placenta, gonads and hematopoietic and nervous systems...
  73. ncbi Hematopoietic receptors of class III receptor-type tyrosine kinases
    O Rosnet
    , U 119 INSERM, Marseille, France
    Crit Rev Oncog 4:595-613. 1993
    ..The structural, biochemical, functional, and pathological features of these three receptors and genes are reviewed...
  74. ncbi A third human CBL gene is on chromosome 19
    V Ollendorff
    U 119 INSERM, 27 Bd Lei Roure, 13009 Marseille, France
    Int J Oncol 13:1159-61. 1998
    ..2-13.3 region where CBLc is located shows paralogy with two other regions of the human genome, 3q22-q27 and 11q22-q24 where CBLb and CBLa are located, respectively. Genes from several other families are located in these regions...
  75. ncbi Characterization of the region of the short arm of chromosome 8 amplified in breast carcinoma
    A Dib
    Laboratoire d Oncologie Moleculaire, U 119 INSERM, Marseille, France
    Oncogene 10:995-1001. 1995
    ..The precise localization and YAC cloning of the core of the amplicon will allow to isolate a putative oncogene involved in mammary carcinogenesis...
  76. pmc p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results
    J Jacquemier
    , Institut Paoli Calmettes, Marseille, France
    Br J Cancer 69:846-52. 1994
    ..In this series p53 expression was not a marker of early recurrence...
  77. ncbi Intracellular trafficking of LET-756, a fibroblast growth factor of C. elegans, is controlled by a balance of export and nuclear signals
    Cornel Popovici
    Institut de Cancérologie de Marseille, Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes et UMR599 Inserm, 27 Bd Lei Roure, 13009 Marseille, France
    Exp Cell Res 312:1484-95. 2006
    ..We propose that LET-756 exerts its functions through a balance between secreted and nuclear forms due to two opposite addressing signals, (i) synergy of several NLS and (ii) attenuated secretion signal...
  78. pmc Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Cancer Res 69:1302-13. 2009
    ....
  79. ncbi Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene
    Cornel Popovici
    Département d Oncologie Moléculaire, Institut Paoli Calmettes, Marseille, France
    Genes Chromosomes Cancer 35:204-18. 2002
    ..Additional experiments using comparative genomic hybridization provided further information on the genomic context in which the t(3;20)(p14;p11) reciprocal translocation was found...
  80. ncbi A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene
    José Adélaïde
    Département d Oncologie Moléculaire, Laboratoires de Cytogénétique Moléculaire et de Pathologie Moléculaire, U119 Institut National de la Santé et de la Recherche Médicale INSERM and Institut Paoli Calmettes IPC, Marseille, France
    Genes Chromosomes Cancer 37:333-45. 2003
    ..PCR analysis of reverse-transcribed cell line RNAs revealed an extensive complexity of the NRG1 transcripts but failed to detect a consistent pattern of mRNA isoforms in the cell lines with NRG1 breakpoint...
  81. ncbi An evolutionary history of the FGF superfamily
    Cornel Popovici
    Laboratory of Molecular Oncology, Marseille Cancer Institute, UMR599, 27 Bd Lei Roure, 13009 Marseille, France
    Bioessays 27:849-57. 2005
    ..A second expansion, which took place during euchordate evolution, is associated with genome duplications. It increased the number of members in the families. Subsequent losses reduced that number to the present-day figures...
  82. ncbi Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact
    F Eisinger
    Department of Genetic Oncology and Cancer Control INSERM EPI 9939, Marseille, France
    Int J Oncol 18:5-10. 2001
    ..Since autonomy of choice is the root of western ethics, cancer prone women should be informed about the low but valuable expected reduction of incidence of breast cancer using Tamoxifen preventive therapy...
  83. ncbi Phylogenetic analysis of Ciona intestinalis gene superfamilies supports the hypothesis of successive gene expansions
    Magalie Leveugle
    Département d Oncologie Moléculaire, Unite 119 INSERM, IFR57, Marseille, France
    J Mol Evol 58:168-81. 2004
    ..They also indicate that Ciona intestinalis genome will be a very valuable tool for evolutionary analyses...
  84. ncbi Interaction between two ubiquitin-protein isopeptide ligases of different classes, CBLC and AIP4/ITCH
    Jean Remy Courbard
    Département d Oncologie Moléculaire, U119 INSERM, 27 Boulevard Lei Roure, 13009 Marseille and Ipsogen SA, Institut Paoli Calmettes, 3009 Marseille, France
    J Biol Chem 277:45267-75. 2002
    ..Finally, coexpressing CBLC and AIP4 induces a down-regulation of EGFR signaling. In conclusion, our data demonstrate that two E3 ligases of different classes can interact and cooperate to down-regulate EGFR signaling...
  85. pmc ParaDB: a tool for paralogy mapping in vertebrate genomes
    Magalie Leveugle
    Laboratoire d Oncologie Moleculaire, Unite 119 INSERM, Marseille, France
    Nucleic Acids Res 31:63-7. 2003
    ..In addition, we provide BLAST results for each protein sequence, InParanoid orthologs and 'In-Paralogs' data, previously established paralogy data, and, to compare vertebrates and Drosophila, orthology data...
  86. pmc Retinoid signaling regulates breast cancer stem cell differentiation
    Christophe Ginestier
    Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm Institut Paoli Calmettes, Marseilles, France
    Cell Cycle 8:3297-302. 2009
    ..These pathways regulate breast CSCs biology and their inhibition may provide novel therapeutic approaches to target breast CSCs...
  87. pmc Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer
    Emmanuelle Charafe-Jauffret
    Department of Molecular Oncology, Institut Paoli Calmettes UMR891 Institut National de la Sante et de la Recherche Medicale, Universite de la Mediterranee, Marseille Cancer Research Center, Marseille, France
    Clin Cancer Res 16:45-55. 2010
    ..To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this aggressive type of breast cancer...
  88. pmc CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
    Christophe Ginestier
    University of Michigan Comprehensive Cancer Center, Department of Internal Medicine Oncology, Ann Arbor, Michigan 48109 0015, USA
    J Clin Invest 120:485-97. 2010
    ..Our data therefore suggest that CXCR1 blockade may provide a novel means of targeting and eliminating breast CSCs...
  89. ncbi Identification and validation of an ERBB2 gene expression signature in breast cancers
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and UMR119 Inserm, IFR57, and Faculté de Médecine, Universite de la Mediterranee, Marseille, France
    Oncogene 23:2564-75. 2004
    ..Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples...
  90. ncbi The LAP family: a phylogenetic point of view
    Marie Josée Santoni
    U119 INSERM, Molecular Oncology and Institut Paoli Calmettes, Molecular Pharmacology, 27, Bd Lei Roure, 13009 Marseille, France
    Trends Genet 18:494-7. 2002
    ..We propose a functional hypothesis for the origin of this protein family in bilaterians, and give a phylogenetic interpretation of their diversity...
  91. ncbi Caenorhabditis elegans receptors related to mammalian vascular endothelial growth factor receptors are expressed in neural cells
    Cornel Popovici
    Molecular Oncology, INSERM U119, 27 Boulevard Lei Roure, 13009 Marseille, France
    Neurosci Lett 329:116-20. 2002
    ..1) in the ALA neuron. In mammals, the VEGFRs are associated with angiogenesis and neurogenesis. We provide here the first observation that these molecules may be primarily and solely involved in neurogenesis in a living organism...
  92. ncbi TACC1-chTOG-Aurora A protein complex in breast cancer
    Nathalie Conte
    Department of Molecular Oncology, U119 INSERM, Institut Paoli Calmettes, IFR57, Marseille, France
    Oncogene 22:8102-16. 2003
    ....
  93. pmc CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines
    Gwladys Zabouo
    Institut Paoli Calmettes, Centre de Ressources Biologiques en Oncologie, Centre de Thérapie Cellulaire et Génique, Marseille, France
    Breast Cancer Res 11:R1. 2009
    ..Studies of CD146 expression and function in breast cancer remain scarce except for a report concluding that CD146 could act as a tumor suppressor in breast carcinogenesis...
  94. ncbi Interaction between Erbin and a Catenin-related protein in epithelial cells
    Fanny Jaulin-Bastard
    U119 INSERM, Molecular Oncology, Institut Paoli Calmettes, Molecular Pharmacology, 27 boulevard Lei Roure 13009 Marseille, France
    J Biol Chem 277:2869-75. 2002
    ..We propose that Erbin is connected by p0071 to cytoskeletal networks in an interaction crucial for epithelial homeostasis...
  95. ncbi Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators
    Nathalie Conte
    Département d Oncologie Moléculaire, U119 INSERM, 27 Bd Lei Roure, 13009, Marseille, France
    Oncogene 21:5619-30. 2002
    ..We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes...
  96. ncbi Typical medullary breast carcinomas have a basal/myoepithelial phenotype
    Jocelyne Jacquemier
    Marseille Cancer Institute, Molecular Oncology Department, UMR599 INSERM and Paoli Calmettes Institute, Marseille, France
    J Pathol 207:260-8. 2005
    ..In multivariate analysis with logistic regression, TMBC was defined by the association of P-cadherin (R=2.29), MIB1 > 50 (R=3.80), ERBB2 negativity (R=2.24) and p53 positivity (RR=1.45)...
  97. pmc Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes
    Anthony Goncalves
    Department of Molecular Pharmacology, Marseille Research Cancer Center, Marseille, France
    Mol Cell Proteomics 7:1420-33. 2008
    ..Our study shows the potential of integrated genomics and proteomics profiling to improve molecular knowledge of complex tumor phenotypes and identify biomarkers with valuable diagnostic or prognostic values...
  98. doi A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells
    Guoqiang Hua
    Universite de la Mediterranee, Institut Paoli Calmettes, Centre de Cancérologie de Marseille, Marseille, France
    Mol Cancer Res 7:402-14. 2009
    ..We propose that the negative feedback loop linking ERBB2 and GATA4 plays a role in the transcriptional dysregulation of ERBB2 gene expression in breast cancer...
  99. ncbi Loss of heterozygosity at microsatellite markers from region p11-21 of chromosome 8 in microdissected breast tumor but not in peritumoral cells
    Emmanuelle Charafe-Jauffret
    Département d Oncologie Moléculaire, Institut Paoli Calmettes IPC, Marseille, France
    Int J Oncol 21:989-96. 2002
    ..In most samples, the TACC1 gene product was downregulated in tumor cells as compared to normal cells. Our results show that the centromeric portion of chromosome arm 8p is frequently altered in breast tumor cells...
  100. ncbi Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer
    Christophe Ginestier
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Int J Cancer 107:854-62. 2003
    ..37 (1.21-4.64; p = 0.03). Thus, among the patients who present with tumors of apparent good prognosis, FHIT is an independent prognostic factor that distinguishes a subgroup of patients who could benefit from adjuvant treatment...
  101. ncbi ETV6 gene rearrangements in invasive breast carcinoma
    Anne Letessier
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Institut Paoli Calmettes and UMR599 INSERM, Marseille, France
    Genes Chromosomes Cancer 44:103-8. 2005
    ..Of these samples, signal of sufficient quality for screening by FISH was obtained for 356. Five cases (one lobular, one nontypical secretory, one mixed, and two ductal carcinomas) showed ETV6 rearrangement...